Prague 5

• A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy of Transfer Factor TFI Treatment by Assessing the Numb … Ended recruitment
  2024-516879-32-00 5 2025-06-13 • Recurrent respiratory infections • Recurrent urinary tract infectio
• LUCIA: A Phase 3 randomized, double-masked study comparing the efficacy of EYP-1901 against aflibercept Ended recruitment
  2024-518030-83-00 5 2025-06-05 Wet age-related macular degeneration (wAMD)
• Phase 2 Study of CVN424 Ended recruitment
  2024-516811-25-00 4 2025-05-15 Parkinson Disease
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration … Ended recruitment
  2024-515022-88-00 5 2025-03-03 Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA
• Crohn's Disease: Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn’s Disease Ended recruitment
  2024-516023-13-00 5 2025-01-23 Crohn's disease
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema … Ended recruitment
  2024-510944-30-00 10 2024-11-22 Diabetic Macular Edema
• ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Sub … Ended recruitment
  2024-511482-11-00 5 2024-11-20 Dry Age-Related Macular Degeneration (Dry AMD)
• A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended recruitment
  2024-511213-38-00 4 2024-10-15 Coeliac disease
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil … Ended recruitment
  2023-506029-12-00 5 2024-04-03 Migraine
• A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either … Ended recruitment
  2023-503357-35-00 4 2024-03-20 Non-small Cell Lung Cancer (NSCLC)
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended recruitment
  2023-504827-17-00 5 2024-03-18 Chronic migraine
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended recruitment
  2023-504839-40-00 5 2024-03-18 Episodic Migraine
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended recruitment
  2022-502593-17-00 5 2023-09-19 Locally advanced or metastatic hormone receptor (HR)-positive, human e
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely … Ended recruitment
  2023-504719-34-00 5 2023-02-21 Moderate to Severly Active Ulcerative Colitis
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA … Ended recruitment
  2023-506241-30-00 5 2021-11-30 Advanced Colorectal Cancer with KRAS G12C Mutation
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506256-25-00 5 2021-10-20 Active Psoriatic Arthritis

Showing 49–72 of 125 trials